GH Guardant Health, Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 2-year channel rising
Price is between the lines.
- 2-year channel
- US$125.43 – US$196.76 · rising, more than +100% a year
- Price in channel
- 75% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$196.76
- Turns bearish below
- US$125.43
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 2:55 AM ET (57 h ago)
- Daily close
- Upper trend line (2 years)
- Lower trend line (2 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$162.70
level as at 5 Dec 2026
Our target
US$207.07
by 27 Jan 2027
Projected move
27.3%
gross, before costs
Price is between our buy and target.
Target: the projected upper line.
This move size: reached in 63% of 8 past stretches, typically in 90 days. (0.30% per day)
- Upper line touches
- 4
- Lower line touches
- 3
- Fit confidence
- 40%
- Fitted
- 1 Nov 2026
Company information
About Guardant Health, Inc.
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Helmy Eltoukhy
- Employees
- 2,498
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$24.50B
- Enterprise value
- —
- Beta
- 1.58
- Avg volume
- 2.46M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 55.38-182.91
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.